Advanced screening test to improve European colorectal cancer survival rates.

<h3>(Vienna, March 2, 2015) Colorectal cancer is the most common type of GI cancer in Europe, with 342,137 new cases recorded in the EU in 2012. It accounts for about half of all gastrointestinal malignancies in Europe and the annual incidence is predicted to rise by 12% by 2020.</h3>  As early detection results in a 90-95% survival rate, United European Gastroenterology (UEG), is urging all European men and women over 50 to ‘Step Up, Take the Test’ and undertake screening for colorectal cancer. In support of Colorectal Cancer Awareness Month (March), UEG also calls upon all EU countries to evaluate advanced screening techniques, such as a simple faecal immunological test, to help increase uptake and survival rates. Faecal immunochemical testing (FIT) is more advanced than the traditional three sample stool test, guaiac-based faecal occult blood tests (gFOBTs). It requires just a single stool sample to check for the presence of blood, a possible indicator of adenomas or CRC and with an easy collection device, it has been found to increase participation uptake. More importantly, FIT offers substantial clinical benefits due to its superior analytical technique. The gFOBT method relies on simple oxidation which can be adversely affected by the influence of dietary haemoglobin. However, the FIT technique is more sensitive. Specific analysis for haemoglobin detects smaller levels of bleeding and therefore more early cancers as well as more adenomas. The number of false positives is also reduced as there is unlikely to be significant interference from dietary haemoglobin found in faeces. If an adverse result is detected, patients are then referred for a colonoscopy. FIT’s simple collection system and enhanced sensitivity offers an attractive alternative to existing gFOBT stool tests as a first-line screening procedure. It will also make it easier for Europeans at risk to get screened and ensure colorectal cancer gets detected as early as possible, enabling thousands to receive successful treatment,” explains UEG CRC screening expert Dr. Monique van Leerdam, from the Netherlands Cancer Institute. Colorectal cancer is treatable when detected early, yet it is estimated to claim the lives of over 500 Europeans every day. According to the recent Survey of Digestive Health across Europe, although CRC screening programmes are now well established in most European countries, many programmes are still not population based and participation rates vary widely. Rates for colorectal cancer screening programmes vary from as little as 15% in areas of Poland and just 22% in Belgium to a healthier rate of 64% in Norway and 70% in Finland.  However, uptake generally throughout Europe remains alarmingly low, with the percentage of eligible adults screened in many countries falling way short of the 65% rate considered desirable by the European Commission and already achieved in the USA. #screeningsaveslives Notes to Editors: To download a map of CRC Incidence & Mortality in Europe, please follow this link: https://www.ueg.eu/fileadmin/user_upload/documents/Press/CRC_Incidence_Map.pdf To download an infographic about CRC screening please follow this link: https://www.ueg.eu/press/crceurope/ Available for interview The following members of the UEG CRC screening ‘Task Group’ are available for interview: 
  • Thierry Ponchon – Department de Hepato-gastroenterologie, Herriot University Hospital, FRANCE
  • Evelien Dekker - Agaplesion Markus Hospital, Frankfurt, GERMANY
  • Monique van Leerdam - NETHERLANDS Cancer Institute
  • Nurdan Tozun - Acibadem University Hospital, Istanbul, TURKEY
  • Roger Jones - Dept. of General Practice, Kings College London UK
Press contact Justin Wilkes media@ueg.eu Tel:+44(0)1444811099 @UEGMedia About UEG United European Gastroenterology is a professional non-profit organisation combining all the leading European societies concerned with digestive diseases. Together, its member societies represent over 22,000 specialists, working across medicine, surgery, paediatrics, gastrointestinal oncology and endoscopy. Find out more about UEG’s work at www.ueg.eu  References 1. Roberts SE, Samuel DG, Williams JG, et al. Survey of Digestive Health across Europe. Part one: The burden of gastrointestinal diseases and the organisation and delivery of gastroenterology services across Europe. Report for United European Gastroenterology. October 2014. 2. International Agency for Research on Cancer (IARC) 3. Mosen DM, Liles EG, Feldstein AC, et al. Participant uptake of the fecal immunochemical test decreases with the two-sample regimen compared with one-sample FIT. Eur J Cancer Prev. 2014 Nov; 23(6): 516–523 4. Allison JE, Fraser CG, Halloran SP, Young GP. Population screening for colorectal cancer means getting FIT: The past, the present and future of colorectal cancer screening using the fecal immunochemical test for haemoglobin (FIT) 5. Overall USA screening rate, Centers For Disease Control and Prevention, 2010

Scientists identify promising blood biomarkers for colorectal cancer: screening blood test within reach?

(Vienna, October 22, 2014) The search for blood-borne biomarkers that could be used to screen for colorectal cancer (CRC) has uncovered two promising candidates that may one day lead to the development of a simple blood test.

Scientists have been piecing together the molecular events involved in the development of CRC and have identified abnormal DNA methylation patterns and the presence of microRNAs as major players in the carcinogenic process.

Speaking to journalists at the 22nd United European Gastroenterology Week (UEG Week 2014) in Vienna, Austria, Dr Antonio Castells from the Institute of Digestive Diseases Hospital Clinic in Barcelona, Spain, said these were exciting times to be working in CRC biomarker research. “Blood-borne biomarkers are opening up exciting avenues of investigation in colorectal and other cancers,” he said. “We now have a better understanding of the molecular events participating in the development of CRC and these provide valuable targets for both the early detection of CRC and the development of novel treatments.” CRC screening: why do we need a blood test? Colorectal cancer is the third most common cancer worldwide and the second leading cause of cancer-related death in the Western world. Several studies have confirmed that CRC screening is both effective and cost-effective in the average-risk population, with the two recommended strategies being stool tests that identify occult blood or exfoliated DNA associated with cancer, and structural examinations such as colonoscopy that detect both cancer and pre-malignant lesions. “Participation in CRC screening programmes across Europe is worryingly low and there seems little doubt that people are put off by the nature of the current tests,” said Dr Castells. “A simple blood test would encourage more people to come forward for screening, potentially saving thousands of lives every year.” The search for CRC screening biomarkers Cancer biomarkers are biological changes that signal the presence of cancer in the body and are usually related to alterations in DNA, RNA or protein expression.1 Several protein biomarkers of CRC have already been identified, however, none have been useful for CRC screening.1 More recently, researchers investigating tumour-derived DNA in the blood have observed abnormal DNA methylation patterns – specifically, abnormally methylated SEPT9 DNA – in the patients with CRC, suggesting a potential new DNA-based biomarker for screening.1 The second potential screening approach outlined by Dr Castells involves assessing the profile of small, non-coding RNAs, known as microRNAs, which have been shown to be increased in the plasma from patients with CRC.2 A recent study conducted by Dr Castells and colleagues found that patients with CRC or advanced adenomas had a significantly different pattern of microRNA expression compared with healthy individuals, leading the group to conclude that plasma microRNA testing was a promising screening test for CRC that warrants further investigation.2 “Both of these potential new CRC screening approaches have shown promise in preliminary studies and should be explored further in larger cohorts of patients,” he told journalists. “There is no doubt in my mind that having an accurate, blood-based screening method would increase adherence to CRC screening guidelines and reduce the number of patients reluctant to be screened.” References 1.     Summers T, et al. J Cancer 2013; 4: 210–216. 2.     Giráldez MD, et al. Clin Gastroenterol Hepatol 2013;11: 681–688.e3. Notes to Editors About UEG Week UEG Week is the largest and most prestigious gastroenterology meeting in Europe and has developed into a global congress. It attracts over 14,000 participants each year, from more than 120 countries, and numbers are steadily rising. UEG Week provides a forum for basic and clinical scientists from across the globe to present their latest research in digestive and liver diseases, and also features a two-day postgraduate course that brings together top lecturers in their fields for a weekend of interactive learning. From October 18-22, 2014, UEG will connect everyone to its annual meeting via livestream on www.ueg.eu. State-of-the-art lectures of Europe’s largest GI meeting may be followed online from around the world. Include #UEGWeek in your tweets. UEG Week 24/7 features all recorded sessions from UEG Week and provides convenient and direct access to the complete congress material, including E-posters and abstracts. About UEG UEG, or United European Gastroenterology, is a professional non-profit organisation combining all the leading European societies concerned with digestive diseases. Together, its member societies represent over 22,000 specialists, working across medicine, surgery, paediatrics, gastrointestinal oncology and endoscopy. This makes UEG the most comprehensive organisation of its kind in the world, and a unique platform for collaboration and the exchange of knowledge. To advance standards of gastroenterological care and knowledge across Europe and the world, UEG offers numerous activities and initiatives besides UEG Week, including: · UEG Education, the universal source of knowledge in gastroenterology, providing online and classroom courses, a huge online library and delivering the latest GI news, fostering debate and discussion · Training Support, funding for innovative training and educational programmes, as well as international scientific and professional co-operations · UEG Journal, published bi-monthly, covering translational and clinical studies from all areas of gastroenterology · EU Affairs, promoting research, prevention, early diagnosis and treatment of digestive diseases, and helping develop an effective health policy for Europe Find out more about UEG’s work. Visit www.ueg.eu Follow UEG on Twitter @my_ueg and @UEGMedia Press Contacts Samantha Forster Email: media@ueg.eu Tel: +44 (0)1444 811099 Press Release Translations Download press release Download der Pressemitteilung Descarga nota de prensa Télécharger le communiqué de presse Download comunicato stampa Download プレスリリース Download 新闻稿 

Screening for Digestive Health Diseases

Various screening programmes are available throughout Europe for different areas of digestive health. 

<1 2